Table 2 Effects of PFD on hemodynamic parameters in rats with cardiac fibrosis.

From: Pirfenidone controls the feedback loop of the AT1R/p38 MAPK/renin-angiotensin system axis by regulating liver X receptor-α in myocardial infarction-induced cardiac fibrosis

Group

Dose (mg/kg)

LVSP (mmHg)

LVEDP (mmHg)

+dp/dtmax (mmHg/sec)

−dp/dtmax (mmHg/sec)

Sham

—

148.1 ± 7.9

5.8 ± 1.1

10806 ± 702

9141 ± 1173

Model

—

115.7 ± 13.4**

10.1 ± 2.2*

6526 ± 1465**

4666 ± 1591**

PFD

300

129.3 ± 15.4#

11.5 ± 4.2

8663 ± 1596##

6475 ± 1414##

Losartan

20

134.1 ± 7.7##

13.2 ± 3.4

8038 ± 1137#

6147 ± 1088#

  1. Data are reported as means ± SEM (n = 13 for sham group, 12 for model group, 12 for PFD group, and 12 for losartan group). Differences between groups were examined by ANOVA followed by Dunnett’s test. PFD, Pirfenidone; LVSP, left ventricular systolic pressure; LVEDP, left ventricular end-diastolic pressure. *P < 0.05, **P < 0.01 vs. sham group. #P < 0.05, ##P < 0.01 vs. model group.
Back to article page